Vaccine development and implementation decisions need to be guided by accurate and
robust burden of disease data. We developed an innovative systematic framework outlining …

Abstract Group A Streptococcus (Strep A) is responsible for a significant global health and
economic burden. The recent prioritization of Strep A vaccine development by the World …

Group A Streptococcus causes a wide range of diseases from relatively mild infections
including pharyngitis to more severe illnesses such as invasive diseases and rheumatic …

Abstract The World Health Organization published the preferred product characteristics for a
Group A Streptococcus (Strep A) vaccine in 2018. Based on these parameters for the age of …

Abstract Group A Streptococcus (GAS) infections result in a considerable underappreciated
burden of acute and chronic disease globally. A 2018 World Health Assembly resolution …

Strep A: challenges, opportunities, vaccine-based solutions, and economics | npj Vaccines
Skip to main content Thank you for visiting nature.com. You are using a browser version …

Considering the lack of existing evidence on economic burden for diseases caused by
group A Streptococcus, we estimated the economic burden per episode for selected …

Group A streptococci (GAS) are important causes of morbidity and mortality worldwide.
These organisms cause a wide spectrum of disease, ranging from uncomplicated sore throat …

Worldwide, childhood mortality has declined significantly, with improvements in hygiene and
vaccinations against common childhood illnesses, yet newborn mortality remains high …

Abstract Background Despite group B Streptococcus (GBS) being a leading cause of
maternal and infant morbidity and mortality, no vaccine is currently available. To inform …